Loading...
Docoh

Becton, Dickinson And (BDX)

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Company profile

Ticker
BDX, BDXB
Exchange
Website
CEO
Thomas Polen
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Accuri Cytometers, Inc. • Alverix, Inc. • Bard Access Systems, Inc. • Bard Acquisition Sub, Inc. • Bard ASDI, Inc. • Bard Brachytherapy, Inc. • Bard Devices, Inc. • Bard Global Holdings I LLC • Bard Global Holdings II LLC • Bard Global Holdings III LLC ...
IRS number
220760120

BDX stock data

Calendar

4 Aug 22
12 Aug 22
30 Sep 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Sep 21 Sep 20 Sep 19 Sep 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 2.76B 2.76B 2.76B 2.76B 2.76B 2.76B
Cash burn (monthly) 187M 43.58M (no burn) (no burn) 5.33M (no burn)
Cash used (since last report) 272.17M 63.43M n/a n/a 7.76M n/a
Cash remaining 2.49B 2.7B n/a n/a 2.75B n/a
Runway (months of cash) 13.3 61.8 n/a n/a 515.9 n/a

Beta Read what these cash burn values mean

My notes
No notes yet
My annotations
No annotations yet
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
9 Aug 22 Khichi Samrat S. Common Stock Sale back to company Dispose D No No 260.44 5,194 1.35M 13,223
9 Aug 22 Khichi Samrat S. Common Stock Option exercise Acquire M No No 108.25 12,489 1.35M 18,417
9 Aug 22 Khichi Samrat S. Common Stock Sell Dispose S No Yes 260.44 9,185 2.39M 5,928
9 Aug 22 Khichi Samrat S. Common Stock Sale back to company Dispose D No No 260.44 5,141 1.34M 15,113
9 Aug 22 Khichi Samrat S. Common Stock Option exercise Acquire M No No 93.49 14,326 1.34M 20,254
9 Aug 22 Khichi Samrat S. Stock Appreciation Rights Common Stock Option exercise Acquire M No No 108.25 12,489 1.35M 0
9 Aug 22 Khichi Samrat S. Stock Appreciation Rights Common Stock Option exercise Acquire M No No 93.49 14,326 1.34M 0
9 Aug 22 Thomas E Polen Jr Common Stock Sell Dispose S No Yes 260 1,652 429.52K 28,878
9 Aug 22 Thomas E Polen Jr Common Stock Sale back to company Dispose D No No 260 2,173 564.98K 30,530
9 Aug 22 Thomas E Polen Jr Common Stock Option exercise Acquire M No No 147.68 3,825 564.88K 32,703
82.7% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 1526 1528 -0.1%
Opened positions 125 207 -39.6%
Closed positions 127 116 +9.5%
Increased positions 557 569 -2.1%
Reduced positions 568 507 +12.0%
13F shares Current Prev Q Change
Total value 62.15B 61.7B +0.7%
Total shares 235.73M 245.43M -3.9%
Total puts 777.6K 1.13M -31.0%
Total calls 787.04K 812.31K -3.1%
Total put/call ratio 1.0 1.4 -28.8%
Largest owners Shares Value Change
Vanguard 24.49M $6.51B +1.3%
BLK Blackrock 20.67M $5.5B -0.1%
TROW T. Rowe Price 12.85M $3.42B -33.5%
STT State Street 12.58M $3.35B -1.0%
Wellington Management 11.35M $3.02B +0.3%
MS Morgan Stanley 7.81M $2.08B -17.6%
Parnassus Investments 5.16M $1.37B +1.2%
Geode Capital Management 4.61M $1.22B +2.5%
Generation Investment Management 4.5M $1.2B -9.0%
Massachusetts Financial Services 4.49M $1.2B +7.1%
Largest transactions Shares Bought/sold Change
TROW T. Rowe Price 12.85M -6.48M -33.5%
Norges Bank 0 -2.64M EXIT
CFS Investment Advisory Services 1.68M +1.68M +26720.3%
MS Morgan Stanley 7.81M -1.67M -17.6%
MKFCF Mackenzie Financial 2.37M +1.05M +79.4%
American Century Companies 1.01M -730.28K -41.9%
JPM JPMorgan Chase & Co. 4.37M -675.92K -13.4%
PRU Prudential Financial 314.43K -487.88K -60.8%
IVZ Invesco 3.55M +471.73K +15.3%
Generation Investment Management 4.5M -443.86K -9.0%

Financial report summary

?
Risks
  • A downturn in economic conditions could adversely affect our operations.
  • The medical technology industry is very competitive.
  • We are subject to foreign currency exchange risk.
  • Our future growth is dependent in part upon the development of new products, and there can be no assurance that such products will be developed.
  • Our international operations subject us to certain business risks.
  • Reductions in customers’ research budgets or government funding may adversely affect our business.
  • We need to attract and retain key employees to be competitive.
  • Breaches of our information systems could have a material adverse effect on our operations.
  • A reduction or interruption in the supply of certain raw materials and components could adversely affect our operating results.
  • Interruption of our manufacturing or sterilization operations could adversely affect our business.
  • Our business and operations are subject to risks related to climate change.
  • We are subject to lawsuits.
  • We are subject to extensive regulation.
  • Defects or quality issues associated with our products could adversely affect the results of our operations.
  • Our operations are dependent in part on patents and other intellectual property assets.
  • We may not be able to service all of our indebtedness.
  • The agreements that govern our indebtedness impose restrictions that may affect our ability to operate our businesses.
  • Risks relating to proposed spin-off.
  • We cannot guarantee that any of our strategic acquisitions, investments or alliances will be successful.
  • Natural disasters, war and other events could adversely affect our future revenues and operating income.
Management Discussion
  • The Medical segment’s revenue growth in 2021 was aided by a favorable comparison to 2020, which was impacted by COVID-19 pandemic-related declines, particularly in the United States and China. These prior-year pandemic-related declines impacted our Medication Delivery Solutions unit, and to a lesser extent, the
  • Diabetes Care unit. Fiscal year 2021 revenue growth in the Medication Delivery Solutions unit reflected strong demand for our core offerings, including U.S. demand for catheters and vascular care products, as well as strong global demand for syringes resulting from COVID-19 vaccination efforts. In the Medication Management
  • Solutions unit, lower revenues in 2021 reflected an unfavorable comparison to 2020, which benefited from global pandemic-related infusion pump orders. Growth in the Diabetes Care unit benefited from the timing of sales, slightly better than expected market demand and a favorable comparison to 2020, which was impacted by pandemic-related declines. The Pharmaceutical Systems unit’s revenue growth in 2021 reflected continued strong growth that is being driven by demand for our pre-filled devices and is enabled by capacity expansion efforts. Demand for pre-filled devices is being aided by the vial to pre-filled device conversion for biologics, vaccines, and other injectable drugs.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: assigned, assumed, BBB, derecognize, discovery, eliminated, EMA, equaled, flat, influence, intrinsic, larger, Noncurrent, Parata, peak, pharmacy, postretirement, preserved, Pretrial, recast, reconstruction, relaunch, residual, RotarexTM, throughput, treated, turnover, unavailability, unvested, VenovoTM, vested
Removed: discrete, disease, Investor, reinvestment, routine, spread, supplier, valuation, weaker

Patents

Utility
Syringe-based Delivery Device for a Vascular Access Instrument
11 Aug 22
A delivery device for delivering an instrument into a catheter assembly may include a syringe having a barrel and a plunger movable within the barrel.
Utility
Pen Assembly
11 Aug 22
A needle magazine (30) comprising a plurality of cavities (38) each carrying a needle (74) fixed to a needle post (70), a first seal (46) disposed at a proximal end of each of the plurality of cavities (38), and a second seal (48) disposed at a distal end of each of the plurality of cavities (38), wherein in a first position of the needle post (70), the needle (74) is enclosed between the first and second seals (46, 48), in a second position of the needle post (70), the first seal (46) is pierced and the needle (74) pierces and extends through the second seal (48) for medication delivery, and in a third position of the needle post (70), the needle (74) no longer extends through the second seal (48) and is ready for disposal.
Utility
Intraosseous Modular Power
11 Aug 22
An intraosseous access system, including an access assembly having a needle configured to drill into bone via rotation of the needle and a driver.
Utility
Universal Connector or Cap for Male and Female Threaded Fittings
11 Aug 22
A cap is described for connection to a medical connector, the cap includes a housing having a top wall and sidewall forming a first cavity, and a removable or integrally formed protrusion.
Utility
Cartridge Adapter for Drug Delivery Device
11 Aug 22
A cartridge adapter for a drug delivery device, the cartridge adapter includes a body having a first end and a second end positioned opposite the first end, with the body including a first clamp member, a second clamp member spaced from the first clamp member, and a connection interface configured to engage a corresponding connection interface of a drug delivery device.